UnknownNCT06530290
Evaluating the Effect of Mirtazapine on Anxiety in Parkinson's Disease Patients
Medication studyAges 18+Iran
Understand this study
Who could participate?
Listed age limits: from 18 years.
- Listed locations
- TehranSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: June 1, 2022
- Recruitment status
- Unknown
- Enrollment listed in the registry
- 64
- Sponsor
- Leila Dargahi. PharmD PhD
- Sponsor type
- Individual investigator
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Iran
- Age range
- Over 18 Years
- Official registry ID
- NCT06530290
- Official title
Show the full official title
Evaluating the Effect of Mirtazapine on Anxiety in Parkinson's Disease Patients; a Randomized Double-blinded Placebo-controlled Clinical Trial
Recruitment & locations
Status unknownThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Tehran
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Leila Dargahi. PharmD PhD.
Does this study involve medication?
Yes. The study involves medication, including Mirtazapine 15 MG and Placebo.
Who can participate?
Listed age limits: from 18 years.
